IJMS, Vol. 25, Pages 10820: Advancements in the Development of Anti-SARS-CoV-2 Therapeutics

IJMS, Vol. 25, Pages 10820: Advancements in the Development of Anti-SARS-CoV-2 Therapeutics

International Journal of Molecular Sciences doi: 10.3390/ijms251910820

Authors: Junjie Huang Qianqian Ma Zhengding Su Xiyao Cheng

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes COVID-19, and so far, it has occurred five noteworthy variants of concern (VOC). SARS-CoV-2 invades cells by contacting its Spike (S) protein to its receptor on the host cell, angiotensin-converting enzyme 2 (ACE2). However, the high frequency of mutations in the S protein has limited the effectiveness of existing drugs against SARS-CoV-2 variants, particularly the Omicron variant. Therefore, it is critical to develop drugs that have highly effective antiviral activity against both SARS-CoV-2 and its variants in the future. This review provides an overview of the mechanism of SARS-CoV-2 infection and the current progress on anti-SARS-CoV-2 drugs.